- Home
- GOSS vs EGHT Comparison
GOSS vs EGHT Comparison
Compare GOSS & EGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- EGHT
- Stock Information
- Founded
- GOSS 2015
- EGHT 1987
- Country
- GOSS United States
- EGHT United States
- Employees
- GOSS N/A
- EGHT N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- EGHT EDP Services
- Sector
- GOSS Health Care
- EGHT Technology
- Exchange
- GOSS Nasdaq
- EGHT Nasdaq
- Market Cap
- GOSS 246.6M
- EGHT 250.2M
- IPO Year
- GOSS 2019
- EGHT 1997
- Fundamental
- Price
- GOSS $1.07
- EGHT $2.05
- Analyst Decision
- GOSS Strong Buy
- EGHT Buy
- Analyst Count
- GOSS 5
- EGHT 6
- Target Price
- GOSS $9.20
- EGHT $2.83
- AVG Volume (30 Days)
- GOSS 989.6K
- EGHT 908.3K
- Earning Date
- GOSS 11-07-2024
- EGHT 10-30-2024
- Dividend Yield
- GOSS N/A
- EGHT N/A
- EPS Growth
- GOSS N/A
- EGHT N/A
- EPS
- GOSS N/A
- EGHT N/A
- Revenue
- GOSS $95,842,000.00
- EGHT $723,565,000.00
- Revenue This Year
- GOSS N/A
- EGHT $0.85
- Revenue Next Year
- GOSS N/A
- EGHT $2.15
- P/E Ratio
- GOSS N/A
- EGHT N/A
- Revenue Growth
- GOSS N/A
- EGHT N/A
- 52 Week Low
- GOSS $0.45
- EGHT $1.51
- 52 Week High
- GOSS $1.60
- EGHT $3.92
- Technical
- Relative Strength Index (RSI)
- GOSS 62.62
- EGHT 63.12
- Support Level
- GOSS $0.98
- EGHT $1.89
- Resistance Level
- GOSS $1.09
- EGHT $2.20
- Average True Range (ATR)
- GOSS 0.07
- EGHT 0.09
- MACD
- GOSS 0.01
- EGHT 0.04
- Stochastic Oscillator
- GOSS 83.22
- EGHT 90.00
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About EGHT 8x8 Inc
8x8 Inc provides contact-center-as-a-service and unified-communications-as-a-service software applications to approximately 2.5 million users. The company's unified platform enables omnichannel communication to assist employees in communicating across voice, video, text, chat, and contact centers. The Company also generates revenue from sales of hardware and professional services, which are complementary to the delivery of its integrated technology platform.. Geographically, it derives a majority of revenue from the United States.